Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

The Stock Day Podcast welcomed Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal,” “Cocrystal Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Co-CEO and CFO of the Company Jim Martin joined Stock Day host Everett Jolly.  Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy